查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2161667

再生醫學市場：依產品、應用、地區和競爭格局分類－全球預測至2031年

Regenerative Medicine Market by Product (Stem Cell, Immunotherapy, Gene Therapy, Tissue Engineering), Application (Musculoskeletal, Cancer, Dermatology, CVD, Ophthalmology, Neurology), Region, Competition - Global Forecast to 2031
出版日期: | 出版商: MarketsandMarkets | 英文 296 Pages | 訂單完成後即時交付

價格

預計再生醫學市場將從 2026 年的 239 億美元成長到 2031 年的 626.9 億美元，預測期內複合年成長率為 21.3%。

預計未來幾年，市場成長將受到新興治療領域廣泛發展以及主要市場參與者之間合作與夥伴關係的推動。此外，人們對個人化醫療日益成長的關注以及再生醫學監管的核准增加，預計也將為市場帶來顯著成長。

調查範圍
調查期 2026-2031
基準年 2025
預測期 2026-2031
計算單位 金額（百萬美元）
部分 按產品和治療領域
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

然而，缺乏長期數據、倫理和法律問題以及高昂的治療費用預計將會抑制市場成長。

再生醫學市場-IMG1

“細胞療法領域在再生醫學市場中佔據主導地位。”

依產品分類，全球再生醫學市場可分為基因療法、細胞療法（幹細胞療法[細胞移植、幹細胞療法產品{自體療法、異體療法}、以細胞為基礎的免疫療法產品]）及組織工程產品。由於幹細胞療法（包括CAR-T療法）和基於細胞的免疫療法的應用日益廣泛，以及在腫瘤學、肌肉骨骼疾病、自體免疫疾病和其他治療領域臨床應用的不斷成長，細胞療法領域佔據市場主導地位。

“到2025年，肌肉骨骼疾病領域將佔據最大的市場佔有率。”

依治療領域分類，再生醫學市場可分為腫瘤學、肌肉骨骼疾病、神經病學、眼科學、皮膚病學和創傷護理、心血管疾病等領域。預計到2025年，肌肉骨骼疾病領域將佔據再生醫學市場最大的佔有率，這主要得益於整形外科和退化性疾病的高發病率，以及再生醫學在軟骨修復、骨骼再生、肌腱和韌帶損傷以及骨關節炎等領域的日益普及。

“預計亞太地區將在全球再生醫學市場中實現顯著成長。”

再生醫學市場按地區分類為北美、歐洲、亞太、拉丁美洲以及中東和非洲。預計亞太地區在預測期內將以顯著的複合年成長率成長。慢性疾病負擔沉重、人均收入不斷提高以及對新技術的需求日益成長，預計將推動該地區再生醫學市場的成長。

本報告所進行的主要訪談依下列類別分類：

  • 依受訪者統計：供給面下降 80%，需求面下降 20%
  • 按職位（供應方）：經理 - 45%，首席主管和總監 - 30%，高階主管 - 25%
  • 區域細分：北美 -55%，歐洲 -10%，亞太地區 -20%，拉丁美洲 -10%，中東和非洲 -5%

調查範圍：

本報告詳細概述了再生醫學市場，旨在評估各細分市場（包括產品、治療領域和地區）的市場規模和未來成長潛力。此外，該報告還對主要市場參與者進行了詳細的競爭分析，包括公司簡介、近期發展動態和關鍵市場策略。

購買本報告的主要好處：

本報告透過提供再生醫學市場及其細分市場最準確的銷售預測，幫助市場領導者和新參與企業更了解市場。報告也有助於相關人員深入了解競爭格局，明確自身業務定位，並制定合適的打入市場策略。透過本報告，相關人員可以掌握市場趨勢，並獲取有關關鍵市場促進因素、限制因素、機會和挑戰的資訊。

本報告深入分析了以下幾點：

  • 關鍵促進因素（對個人化醫療的日益關注、再生醫學法規核准的激增、主要市場參與者之間合作與夥伴關係的增加以及在新治療領域的應用範圍擴大）、阻礙因素（缺乏長期數據、倫理和法律問題以及高昂的治療成本）、機遇（與人工智慧和巨量資料相結合、利用 3D 列印的潛力以及器官移植的潛力增加）以及器官的經濟成長）以及各種缺乏的全球性的挑戰”
  • 產品開發/創新：對再生醫學市場新推出的產品進行詳細分析。
  • 市場發展：盈利市場的全面資訊－本報告分析了各個地區的再生醫學市場。
  • 市場多元化：有關再生醫學市場的新產品、未開發地區、最新趨勢和投資的全面資訊。
  • 競爭分析：對主要參與者的市場佔有率、成長策略和產品陣容進行詳細評估。

目錄

第1章：引言

第2章執行摘要

第3章重要考察

  • 再生醫學市場概覽
  • 再生醫學市場：按類型和地區分類
  • 再生醫學市場：區域概覽
  • 再生醫學市場佔有率（按產品分類）：2026 年與 2031 年對比

第4章 市場概覽

  • 市場動態
    • 促進因素
    • 抑制因子
    • 機會
    • 任務
  • 未滿足的需求和未開發的領域
  • 相互關聯的市場與跨產業機遇
  • 一級/二級/三級主要公司的策略性舉措

第5章 產業趨勢

  • 波特五力分析
    • 新進入者的威脅
    • 替代品的威脅
    • 買方的議價能力
    • 供應商的議價能力
    • 競爭公司之間的競爭
  • 宏觀經濟展望
    • GDP趨勢與預測
    • 全球再生醫學市場趨勢
  • 價值鏈分析
  • 生態系分析
  • 價格分析
    • 主要公司平均售價趨勢（2023-2025 年）
    • 各地區平均售價（2025 年）
  • 重要會議和活動
  • 影響客戶業務的趨勢和變化
  • 投資和資金籌措趨勢
  • 案例研究分析
  • 2025年美國關稅對再生醫學市場的影響
    • 主要關稅稅率
    • 價格影響分析
    • 對國家和地區的影響
    • 對終端用戶產業的影響

第6章：技術進步、人工智慧的影響、專利、創新與未來應用

  • 主要新興技術
    • 人工智慧驅動的細胞和基因療法的開發
    • 智慧生物材料和可注射支架
  • 相關技術
    • 類器官和晶片器官技術
    • 先進的成像和細胞表徵技術
  • 互補技術
    • 生物反應器和先進的細胞培養系統
    • 細胞增殖和細胞處理技術
  • 技術和產品藍圖
  • 管道分析
  • 未來應用
  • 人工智慧/生成式人工智慧對再生醫學市場的影響
    • 主要應用場景和市場潛力
    • 人工智慧在再生醫學市場應用案例研究
    • 相互關聯的相鄰生態系及其對市場參與者的影響
    • 再生醫學市場中客戶對生成式人工智慧應用的準備情況

第7章：監理情勢與永續性舉措

  • 區域法規和合規性
    • 監管機構、政府機構和其他組織
    • 業界標準
  • 永續發展計劃
  • 監理政策對永續發展措施的影響
  • 認證、標籤和環境標準

第8章：顧客趨勢與購買行為

  • 決策流程
  • 買方相關人員和採購評估標準
    • 採購過程中的關鍵相關人員
    • 依最終使用者分類的再生醫學產品關鍵採購標準。
  • 實施障礙和內部挑戰
  • 各個終端用戶產業尚未滿足的需求
  • 市場盈利

第9章 再生醫學市場：依產品分類

  • 細胞療法
  • 基因治療
  • 組織工程

第10章 再生醫學市場：依治療領域分類

  • 腫瘤學
  • 肌肉骨骼疾病
  • 皮膚病學和創傷護理
  • 心血管疾病
  • 眼科
  • 神經病學
  • 其他治療領域

第11章 再生醫學市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太其他地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲
  • 中東
    • 基因藥物研發計畫正受到越來越多的關注，預計將在未來幾年推動市場成長。
  • 非洲
    • 未來幾年，我們預計合作夥伴關係將持續擴大，這將有助於市場成長。

第12章 競爭格局

  • 主要參與企業的策略/優勢
  • 收入分析（2023-2025）
  • 市佔率分析（2025 年）
  • 企業估值矩陣：主要公司，2025 年
    • 明星公司
    • 新興領導者
    • 玩家種類繁多
    • 參與企業
    • 企業企業發展：主要公司，2025 年
    • 區域趨勢
    • 產品開發
    • 按治療區域分類的發展狀況
  • 公司估值矩陣：新創企業/中小企業，2025 年
    • 先進公司
    • 應對力的公司
    • 充滿活力的公司
    • 起始點
    • 競爭標竿分析：新創企業/中小企業，2025 年
  • 企業估值和財務指標
    • 主要公司的企業估值
    • 主要公司（依產品分類）的財務指標
  • 品牌/產品比較分析
  • 競爭格局
    • 產品發布
    • 交易
    • 業務拓展

第13章：公司簡介

  • 市場上的主要公司
    • NOVARTIS AG
    • GILEAD SCIENCES, INC.
    • SAREPTA THERAPEUTICS, INC.
    • AMGEN, INC.
    • JOHNSON &JOHNSON
    • BIOGEN INC.
    • SMITH+NEPHEW
    • MEDIPOST CO., LTD.
    • JCR PHARMACEUTICALS CO., LTD.
    • CORESTEM, INC.
    • VERICEL CORPORATION
    • MIMEDX GROUP, INC.
    • ORGANOGENESIS INC.
    • MEDTRONIC
    • BRISTOL-MYERS SQUIBB COMPANY
    • AUTOLUS THERAPEUTICS
  • 其他主要公司
    • ORTHOCELL LTD.
    • MESOBLAST LTD.
    • BIORESTORATIVE THERAPIES, INC.
    • PLURISTEM THERAPEUTICS INC.
    • TEGOSCIENCE
    • ANTEROGEN. CO., LTD.
    • BLUEBIRD BIO, INC.
    • STEMPEUTICS RESEARCH PVT. LTD.
    • SIBIONO GENETECH CO. LTD.
    • ASPECT BIOSYSTEMS

第14章調查方法

第15章附錄

Product Code: BT 4419

The regenerative medicine market is projected to reach USD 62.69 billion by 2031 from USD 23.90 billion in 2026, at a CAGR of 21.3% during the forecast period. Factors such as the wide scope in new therapeutic areas and collaborations and partnerships by major market players are predicted to uplift the market in the coming years. Additionally, the rise in the focus on personalized medicine and rising regenerative medicine regulatory approvals is expected to provide lucrative market growth.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD million)
SegmentsBy Product, By Therapeutic area
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa

However, lack of long-term data, ethical & legal concerns, and high cost of treatments are expected to restrict the market growth.

Regenerative Medicine Market - IMG1

"The cell therapy segment held the dominant share in the regenerative medicine market."

Based on product, the global regenerative medicine market is segmented into gene therapy, cell therapy (stem cell therapy [cell transplantations, stem cell therapy products {autologous therapy, allogenic therapy] cell-based immunotherapy products), and tissue engineering products. The dominance of the cell therapy segment is driven by the growing adoption of stem cell therapies and cell-based immunotherapies, including CAR-T therapies, along with increasing clinical applications across oncology, musculoskeletal disorders, autoimmune diseases, and other therapeutic areas.

"The musculoskeletal disorders segment accounted for the largest share of the market in 2025."

Based on therapeutic area, the regenerative medicine market is segmented into oncology, musculoskeletal disorders, neurology, ophthalmology, dermatology & wound care, cardiovascular diseases, and others. The musculoskeletal disorders segment accounted for the largest share of the regenerative medicines market in 2025, driven by the high prevalence of orthopedic and degenerative conditions and the growing adoption of regenerative therapies for cartilage repair, bone regeneration, tendon and ligament injuries, and osteoarthritis.

"Asia Pacific is projected to register significant growth in the global regenerative medicine market."

The regenerative medicine market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Asia Pacific is anticipated to grow at a significant CAGR during the forecast period. High burden of chronic diseases, growing per capita income, and the rising demand for new technologies are expected to support the regenerative medicine market growth in the region.

Primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 80%, and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives - 25%
  • By Region: North America - 55%, Europe -10%, Asia-Pacific - 20%, Latin America - 10%, MEA - 5%

List of Companies Profiled in the Report:

  • Novartis AG (Switzerland)
  • Biogen, Inc. (US)
  • Sarepta Therapeutics, Inc. (US)
  • Gilead Sciences, Inc. (US)
  • Amgen Inc. (US)
  • Smith+Nephew (UK)
  • MEDIPOST Co., Ltd. (Korea)
  • JCR Pharmaceuticals Co., Ltd. (Japan)
  • CORESTEM, Inc. (South Korea)
  • Vericel Corporation (US)
  • MIMEDX Group, Inc. (US)
  • Organogenesis Inc. (US)
  • Medtronic (Ireland)
  • Bristol-Myers Squibb Company (US)
  • Orthocell Ltd. (Australia)
  • Mesoblast Ltd. (Australia)
  • BioRestorative Therapies, Inc. (US)
  • Pluristem Therapeutics Inc. (US)
  • TEGOSCIENCE (South Korea)
  • ANTEROGEN.CO., LTD. (South Korea)
  • Bluebird Bio, Inc. (US)
  • Stempeutics Research Pvt Ltd. (India)
  • Sibiono GeneTech Co., Ltd. (China)
  • Aspect Biosystems Ltd. (Canada)
  • Athersys, Inc. (US)

Research Coverage:

This report provides a detailed picture of the regenerative medicine market. It aims to estimate the size and future growth potential of the market across different segments, such as product, therapeutic area, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall regenerative medicine market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Growing focus on personalized medicine, Steep rise in regulatory approvals in regenerative medicine, Rising collaborations and partnerships by major market players, Increasing scope in new therapeutic areas), restraints (Lack of long-term data, Ethical and legal concerns and high cost of treatments), opportunities (Integration with artificial intelligence and big data, Harnessing the potential of 3D printing, Growing number of organ transplants) and challenges (Lack of favorable reimbursement policies across various regions) influencing the growth of the regenerative medicine market
  • Product Development/Innovation: Detailed insights on newly launched products of the regenerative medicine market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the regenerative medicine market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the regenerative medicine market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Novartis AG (Switzerland), Biogen, Inc. (US), Sarepta Therapeutics, Inc. (US), Gilead Sciences, Inc. (US), Amgen Inc. (US), Smith+Nephew (UK), MEDIPOST Co., Ltd. (Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), and CORESTEM, Inc. (South Korea), among others

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 REGENERATIVE MEDICINE MARKET OVERVIEW
  • 3.2 REGENERATIVE MEDICINE MARKET, BY TYPE & REGION
  • 3.3 REGENERATIVE MEDICINE MARKET: GEOGRAPHIC SNAPSHOT
  • 3.4 REGENERATIVE MEDICINE MARKET SHARE, BY PRODUCT 2026 VS 2031

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Expanding clinical pipeline and increasing commercialization of regenerative therapies
      • 4.2.1.2 Broadening therapeutic applications of regenerative medicine
      • 4.2.1.3 Increased investment and strategic partnerships
      • 4.2.1.4 Advancing regulatory support for regenerative therapies
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High treatment costs and reimbursement constraints
      • 4.2.2.2 Long-term safety and durability uncertainties
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Allogeneic and iPSC-derived "off-the-shelf" cell therapies
      • 4.2.3.2 Clinical translation of tissue engineering and 3D bioprinting
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Shortage of specialized manufacturing infrastructure and skilled personnel
  • 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 THREAT OF NEW ENTRANTS
    • 5.1.2 THREAT OF SUBSTITUTES
    • 5.1.3 BARGAINING POWER OF BUYERS
    • 5.1.4 BARGAINING POWER OF SUPPLIERS
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC OUTLOOK
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS AND FORECAST
    • 5.2.3 TRENDS IN GLOBAL REGENERATIVE MEDICINE MARKET
  • 5.3 VALUE CHAIN ANALYSIS
  • 5.4 ECOSYSTEM ANALYSIS
  • 5.5 PRICING ANALYSIS
    • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
    • 5.5.2 AVERAGE SELLING PRICE, BY REGION (2025)
  • 5.6 KEY CONFERENCES & EVENTS
  • 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.8 INVESTMENT/FUNDING ACTIVITY
  • 5.9 CASE STUDY ANALYSIS
  • 5.10 IMPACT OF 2025 US TARIFFS-REGENERATIVE MEDICINE MARKET
    • 5.10.1 INTRODUCTION
    • 5.10.2 KEY TARIFF RATES
    • 5.10.3 PRICE IMPACT ANALYSIS
    • 5.10.4 IMPACT ON COUNTRIES/REGIONS
      • 5.10.4.1 North America
      • 5.10.4.2 Europe
      • 5.10.4.3 Asia Pacific
    • 5.10.5 IMPACT ON END-USE INDUSTRIES
      • 5.10.5.1 Hospitals
      • 5.10.5.2 Specialty clinics and cancer centers
      • 5.10.5.3 Other specialty care settings

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 AI-DRIVEN CELL & GENE THERAPY DEVELOPMENT
    • 6.1.2 SMART BIOMATERIALS & INJECTABLE SCAFFOLDS
  • 6.2 ADJACENT TECHNOLOGIES
    • 6.2.1 ORGANOID & ORGAN-ON-CHIP TECHNOLOGIES
    • 6.2.2 ADVANCED IMAGING & CELL CHARACTERIZATION TECHNOLOGIES
  • 6.3 COMPLEMENTARY TECHNOLOGIES
    • 6.3.1 BIOREACTORS & ADVANCED CELL CULTURE SYSTEMS
    • 6.3.2 CELL EXPANSION & CELL PROCESSING TECHNOLOGIES
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PIPELINE ANALYSIS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
    • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
    • 6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET
    • 6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
    • 6.7.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE MEDICINE MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

  • 7.1 REGIONAL REGULATIONS AND COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 7.1.2 INDUSTRY STANDARDS
  • 7.2 SUSTAINABILITY INITIATIVES
  • 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.4 CERTIFICATIONS, LABELING, & ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY

9 REGENERATIVE MEDICINE MARKET, BY PRODUCT

  • 9.1 INTRODUCTION
  • 9.2 CELL THERAPY
    • 9.2.1 STEM CELL THERAPY
      • 9.2.1.1 Cell transplantations
        • 9.2.1.1.1 Potential of Allo-SCT in treating AML to drive segmental growth
      • 9.2.1.2 Stem cell therapy products
        • 9.2.1.2.1 Autologous therapy
          • 9.2.1.2.1.1 Low risk of post-treatment complications to support segment growth
        • 9.2.1.2.2 Allogeneic therapy
          • 9.2.1.2.2.1 High potential in disease treatment to ensure demand and development
    • 9.2.2 CELL-BASED IMMUNOTHERAPY
      • 9.2.2.1 Growing adoption of T-cell therapy in cancer treatment to support market growth
  • 9.3 GENE THERAPY
    • 9.3.1 STRONG PRODUCT PIPELINE DUE TO BROADENING APPLICATIONS IN DISEASE TREATMENT TO DRIVE MARKET
  • 9.4 TISSUE ENGINEERING
    • 9.4.1 HIGH DEMAND FOR TISSUE ENGINEERING PRODUCTS IN DERMATOLOGY & WOUND CARE APPLICATIONS TO DRIVE MARKET

10 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA

  • 10.1 INTRODUCTION
  • 10.2 ONCOLOGY
    • 10.2.1 INCREASING STEM CELL TRANSPLANTS TO DRIVE MARKET
  • 10.3 MUSCULOSKELETAL DISORDERS
    • 10.3.1 RISING RESEARCH ON MUSCULOSKELETAL REGENERATION AND PREVALENCE OF ORTHOPEDIC DISORDERS TO DRIVE MARKET
  • 10.4 DERMATOLOGY & WOUND CARE
    • 10.4.1 RISING USE OF WOUND CARE BIOLOGICS TO DRIVE MARKET
  • 10.5 CARDIOVASCULAR DISEASES
    • 10.5.1 INCREASING USE OF MSCS FOR CLINICAL RESEARCH ON IHD TO SUPPORT MARKET GROWTH
  • 10.6 OPHTHALMOLOGY
    • 10.6.1 REGENERATION OF EYE TISSUES FOR AMD TO SUPPORT MARKET GROWTH
  • 10.7 NEUROLOGY
    • 10.7.1 GROWING NUMBER OF GENE THERAPY PRODUCTS APPROVED FOR NEUROLOGICAL DISEASE TREATMENT TO DRIVE MARKET GROWTH
  • 10.8 OTHER THERAPEUTIC AREAS

11 REGENERATIVE MEDICINE MARKET, BY REGION

  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    • 11.2.1 US
      • 11.2.1.1 Rising number of pipeline products for regenerative medicine to drive market
    • 11.2.2 CANADA
      • 11.2.2.1 Rising government initiatives for regenerative medicine research to drive market
  • 11.3 EUROPE
    • 11.3.1 GERMANY
      • 11.3.1.1 Rising focus on clinical research and patent approvals to drive market
    • 11.3.2 UK
      • 11.3.2.1 Incorporating regenerative medicine into commercial healthcare services under NHS to drive market
    • 11.3.3 FRANCE
      • 11.3.3.1 Structured regulatory framework to drive regenerative medicine product pipeline
    • 11.3.4 ITALY
      • 11.3.4.1 Rising prevalence of neurological and cardiovascular disorders to drive market
    • 11.3.5 SPAIN
      • 11.3.5.1 Favorable regulatory environment to drive product pipeline
    • 11.3.6 REST OF EUROPE
  • 11.4 ASIA PACIFIC
    • 11.4.1 CHINA
      • 11.4.1.1 Favorable government support for development of regenerative medicine to drive market
    • 11.4.2 JAPAN
      • 11.4.2.1 Regulatory amendments to pharmaceutical legislation to drive commercialization of therapies
    • 11.4.3 INDIA
      • 11.4.3.1 Introduction of novel therapies for CVD and cancer to support market growth
    • 11.4.4 SOUTH KOREA
      • 11.4.4.1 Strong research base and availability of funds to support market growth
    • 11.4.5 AUSTRALIA
      • 11.4.5.1 Increasing incidence of sports injuries to support market growth
    • 11.4.6 REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    • 11.5.1 BRAZIL
      • 11.5.1.1 Gradual increase in pharmaceutical R&D to support market growth
    • 11.5.2 REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST
    • 11.6.1 GROWING FOCUS ON GENETIC MEDICINE DEVELOPMENT PROJECTS TO DRIVE MARKET GROWTH IN COMING YEARS
  • 11.7 AFRICA
    • 11.7.1 RISING COLLABORATIONS TO SUPPORT MARKET GROWTH IN COMING YEARS

12 COMPETITIVE LANDSCAPE

  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.3 REVENUE ANALYSIS, 2023-2025
  • 12.4 MARKET SHARE ANALYSIS, 2025
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 12.5.1 STARS
    • 12.5.2 EMERGING LEADERS
    • 12.5.3 PERVASIVE PLAYERS
    • 12.5.4 PARTICIPANTS
    • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 12.5.5.1 Company footprint
    • 12.5.6 REGION FOOTPRINT
    • 12.5.7 PRODUCT FOOTPRINT
    • 12.5.8 THERAPEUTIC AREA FOOTPRINT
  • 12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
    • 12.6.1 PROGRESSIVE COMPANIES
    • 12.6.2 RESPONSIVE COMPANIES
    • 12.6.3 DYNAMIC COMPANIES
    • 12.6.4 STARTING BLOCKS
    • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
      • 12.6.5.1 Detailed list of key startups/SMEs
      • 12.6.5.2 Competitive benchmarking of startups/SMEs
  • 12.7 COMPANY VALUATION AND FINANCIAL METRICS
    • 12.7.1 VALUATION OF KEY PLAYERS
    • 12.7.2 FINANCIAL METRICS OF KEY PLAYERS (PRODUCTS)
  • 12.8 RAND/PRODUCT COMPARATIVE ANALYSIS
  • 12.9 COMPETITIVE SCENARIO
    • 12.9.1 PRODUCT LAUNCHES
    • 12.9.2 DEALS
    • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

  • 13.1 KEY MARKET PLAYERS
    • 13.1.1 NOVARTIS AG
      • 13.1.1.1 Business overview
      • 13.1.1.2 Products offered
      • 13.1.1.3 Recent developments
        • 13.1.1.3.1 Product approvals
        • 13.1.1.3.2 Deals
        • 13.1.1.3.3 Expansions
      • 13.1.1.4 MnM view
        • 13.1.1.4.1 Key Strengths/Right to win
        • 13.1.1.4.2 Strategic choices made
        • 13.1.1.4.3 Weaknesses & competitive threats
    • 13.1.2 GILEAD SCIENCES, INC.
      • 13.1.2.1 Business overview
      • 13.1.2.2 Products offered
      • 13.1.2.3 Recent developments
        • 13.1.2.3.1 Product approvals
        • 13.1.2.3.2 Deals
      • 13.1.2.4 MnM view
        • 13.1.2.4.1 Key strengths
        • 13.1.2.4.2 Strategic choices
        • 13.1.2.4.3 Weaknesses & competitive threats
    • 13.1.3 SAREPTA THERAPEUTICS, INC.
      • 13.1.3.1 Business overview
      • 13.1.3.2 Products offered
      • 13.1.3.3 Recent developments
        • 13.1.3.3.1 Product launches & approvals
        • 13.1.3.3.2 Deals
      • 13.1.3.4 MnM view
        • 13.1.3.4.1 Key strengths
        • 13.1.3.4.2 Strategic choices
        • 13.1.3.4.3 Weaknesses & competitive threats
    • 13.1.4 AMGEN, INC.
      • 13.1.4.1 Business overview
      • 13.1.4.2 Products offered
      • 13.1.4.3 Recent developments
        • 13.1.4.3.1 Deals
      • 13.1.4.4 MnM view
        • 13.1.4.4.1 Key strengths
        • 13.1.4.4.2 Strategic choices
        • 13.1.4.4.3 Weaknesses & competitive threats
    • 13.1.5 JOHNSON & JOHNSON
      • 13.1.5.1 Business overview
      • 13.1.5.2 Products offered
      • 13.1.5.3 Recent developments
        • 13.1.5.3.1 Product approvals
        • 13.1.5.3.2 Deals
      • 13.1.5.4 MnM view
        • 13.1.5.4.1 Key Strengths/Right to win
        • 13.1.5.4.2 Strategic choices made
        • 13.1.5.4.3 Weaknesses & competitive threats
    • 13.1.6 BIOGEN INC.
      • 13.1.6.1 Business overview
      • 13.1.6.2 Products offered
      • 13.1.6.3 Recent developments
        • 13.1.6.3.1 Product approvals
        • 13.1.6.3.2 Expansions
    • 13.1.7 SMITH+NEPHEW
      • 13.1.7.1 Business overview
      • 13.1.7.2 Products offered
    • 13.1.8 MEDIPOST CO., LTD.
      • 13.1.8.1 Business overview
      • 13.1.8.2 Products offered
      • 13.1.8.3 Recent developments
        • 13.1.8.3.1 Deals
        • 13.1.8.3.2 Other developments
    • 13.1.9 JCR PHARMACEUTICALS CO., LTD.
      • 13.1.9.1 Business overview
      • 13.1.9.2 Products offered
    • 13.1.10 CORESTEM, INC.
      • 13.1.10.1 Business overview
      • 13.1.10.2 Products offered
      • 13.1.10.3 Product pipeline
    • 13.1.11 VERICEL CORPORATION
      • 13.1.11.1 Business overview
      • 13.1.11.2 Products offered
      • 13.1.11.3 Recent developments
        • 13.1.11.3.1 Product approvals
    • 13.1.12 MIMEDX GROUP, INC.
      • 13.1.12.1 Business overview
      • 13.1.12.2 Products offered
      • 13.1.12.3 Recent developments
        • 13.1.12.3.1 Product launches
        • 13.1.12.3.2 Deals
    • 13.1.13 ORGANOGENESIS INC.
      • 13.1.13.1 Business overview
      • 13.1.13.2 Products offered
      • 13.1.13.3 Recent developments
        • 13.1.13.3.1 Deals
    • 13.1.14 MEDTRONIC
      • 13.1.14.1 Business overview
      • 13.1.14.2 Products offered
      • 13.1.14.3 Recent developments
        • 13.1.14.3.1 Deals
    • 13.1.15 BRISTOL-MYERS SQUIBB COMPANY
      • 13.1.15.1 Business overview
      • 13.1.15.2 Products offered
      • 13.1.15.3 Recent developments
        • 13.1.15.3.1 Product approvals
        • 13.1.15.3.2 Deals
    • 13.1.16 AUTOLUS THERAPEUTICS
      • 13.1.16.1 Business overview
      • 13.1.16.2 Products offered
      • 13.1.16.3 Recent developments
        • 13.1.16.3.1 Product approvals
        • 13.1.16.3.2 Deals
  • 13.2 OTHER PLAYERS
    • 13.2.1 ORTHOCELL LTD.
    • 13.2.2 MESOBLAST LTD.
    • 13.2.3 BIORESTORATIVE THERAPIES, INC.
    • 13.2.4 PLURISTEM THERAPEUTICS INC.
    • 13.2.5 TEGOSCIENCE
    • 13.2.6 ANTEROGEN. CO., LTD.
    • 13.2.7 BLUEBIRD BIO, INC.
    • 13.2.8 STEMPEUTICS RESEARCH PVT. LTD.
    • 13.2.9 SIBIONO GENETECH CO. LTD.
    • 13.2.10 ASPECT BIOSYSTEMS

14 RESEARCH METHODOLOGY

  • 14.1 RESEARCH DATA
    • 14.1.1 SECONDARY DATA
    • 14.1.2 PRIMARY DATA
  • 14.2 MARKET SIZE ESTIMATION
    • 14.2.1 PRIMARY INSIGHTS
    • 14.2.2 SEGMENT ASSESSMENT METHODOLOGY: REGENERATIVE MEDICINE MARKET
  • 14.3 MARKET BREAKDOWN & DATA TRIANGULATION
  • 14.4 STUDY ASSUMPTIONS
  • 14.5 RISK ANALYSIS

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 REGENERATIVE MEDICINE MARKET: IMPACT ANALYSIS
  • TABLE 2 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 3 REGENERATIVE MEDICINE MARKET: ROLE IN ECOSYSTEM
  • TABLE 4 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2023-2025 (USD)
  • TABLE 5 AVERAGE SELLING PRICE OF PRODUCTS, BY REGION, 2025 (USD)
  • TABLE 6 REGENERATIVE MEDICINE MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 7 REDUCING CAR-T MANUFACTURING TURNAROUND TIME FOR YESCARTA
  • TABLE 8 EXPANDING CAR-T MANUFACTURING CAPACITY TO MEET GLOBAL CARVYKTI DEMAND
  • TABLE 9 EXPANDING BIOMANUFACTURING CAPACITY FOR REGENERATIVE TISSUE PRODUCTS
  • TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 11 INDICATIVE LIST OF PIPELINE PRODUCTS IN PHASE 3, 2025
  • TABLE 12 CASE STUDIES OF AI IMPLEMENTATION IN REGENERATIVE MEDICINE MARKET
  • TABLE 13 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN REGENERATIVE MEDICINE MARKET
  • TABLE 14 LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%)
  • TABLE 16 KEY BUYING CRITERIA, BY END USER
  • TABLE 17 REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 18 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 19 REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 20 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 21 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 22 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 23 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 24 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 25 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 26 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 27 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 29 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 30 REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 31 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 32 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 33 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 34 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL TRANSPLANTATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 35 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 36 REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 37 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 38 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 40 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 41 REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 42 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 43 EUROPE: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 44 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 45 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR AUTOLOGOUS THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 46 REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 47 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 48 EUROPE: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 50 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ALLOGENEIC THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 51 REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 52 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 53 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 55 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL-BASED IMMUNOTHERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 56 APPROVED GENE THERAPIES, 2022
  • TABLE 57 REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 58 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 59 EUROPE: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 61 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR GENE THERAPY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 62 REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 63 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 64 EUROPE: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 66 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR TISSUE ENGINEERING, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 67 REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 68 INDICATIVE LIST OF COMMERCIALIZED REGENERATIVE CELL THERAPIES FOR ONCOLOGY APPLICATIONS
  • TABLE 69 REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 70 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 71 EUROPE: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 73 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR ONCOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 74 REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 75 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 76 EUROPE: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 78 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 79 INDICATIVE LIST OF REGENERATIVE MEDICINE PRODUCTS COMMERCIALIZED FOR TREATMENT OF ACUTE & CHRONIC WOUNDS
  • TABLE 80 REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 81 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 82 EUROPE: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 83 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 84 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR DERMATOLOGY & WOUND CARE, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 85 REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 87 EUROPE: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 89 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 90 LIST OF PIPELINE PRODUCTS FOR REGENERATIVE MEDICINE IN OPHTHALMOLOGY
  • TABLE 91 REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 93 EUROPE: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 96 REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 97 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 98 EUROPE: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 99 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 100 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR NEUROLOGY, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 101 REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 102 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 103 EUROPE: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 105 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 106 REGENERATIVE MEDICINE MARKET, BY REGION, 2023-2031 (USD MILLION)
  • TABLE 107 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 108 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 109 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 110 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 111 NORTH AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 112 NORTH AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 113 US: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 114 US: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 115 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 116 US: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 117 US: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 118 CANADA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 119 CANADA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 120 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 121 CANADA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 122 CANADA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 123 EUROPE: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 124 EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 125 EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 126 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 127 EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 128 EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 129 GERMANY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 130 GERMANY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 131 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 132 GERMANY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 133 GERMANY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 134 UK: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 135 UK: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 136 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 137 UK: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 138 UK: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 139 FRANCE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 140 FRANCE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 141 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 142 FRANCE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 143 FRANCE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 144 ITALY: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 145 ITALY: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 146 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 147 ITALY: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 148 ITALY: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 149 SPAIN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 150 SPAIN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 151 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 152 SPAIN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 153 SPAIN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 154 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 155 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 156 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 157 REST OF EUROPE: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 158 REST OF EUROPE: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 165 CHINA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 166 CHINA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 167 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 168 CHINA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 169 CHINA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 170 JAPAN: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 171 JAPAN: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 172 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 173 JAPAN: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 174 JAPAN: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 175 INDIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 176 INDIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 177 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 178 INDIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 179 INDIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 180 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 181 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 182 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 183 SOUTH KOREA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 184 SOUTH KOREA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 185 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 186 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 187 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 188 AUSTRALIA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 189 AUSTRALIA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 190 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 191 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 192 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 193 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 194 REST OF ASIA PACIFIC: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 195 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
  • TABLE 196 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 197 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 198 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 199 LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 200 LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 201 BRAZIL: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 202 BRAZIL: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 203 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 204 BRAZIL: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 205 BRAZIL: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 206 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 207 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 208 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 209 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 210 REST OF LATIN AMERICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 211 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 212 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 213 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 214 MIDDLE EAST: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 215 MIDDLE EAST: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 216 AFRICA: REGENERATIVE MEDICINE MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
  • TABLE 217 AFRICA: REGENERATIVE MEDICINE MARKET FOR CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 218 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 219 AFRICA: REGENERATIVE MEDICINE MARKET FOR STEM CELL THERAPY PRODUCTS, BY TYPE, 2023-2031 (USD MILLION)
  • TABLE 220 AFRICA: REGENERATIVE MEDICINE MARKET, BY THERAPEUTIC AREA, 2023-2031 (USD MILLION)
  • TABLE 221 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN THE REGENERATIVE MEDICINE MARKET
  • TABLE 222 REGENERATIVE MEDICINE MARKET: DEGREE OF COMPETITION
  • TABLE 223 REGENERATIVE MEDICINE MARKET: REGION FOOTPRINT
  • TABLE 224 REGENERATIVE MEDICINE MARKET: PRODUCT FOOTPRINT
  • TABLE 225 REGENERATIVE MEDICINE MARKET: THERAPEUTIC AREA FOOTPRINT
  • TABLE 226 REGENERATIVE MEDICINE MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 227 REGENERATIVE MEDICINE MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
  • TABLE 228 REGENERATIVE MEDICINE MARKET: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 229 REGENERATIVE MEDICINE MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 230 REGENERATIVE MEDICINE MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 231 NOVARTIS AG: COMPANY OVERVIEW
  • TABLE 232 NOVARTIS AG: PRODUCTS OFFERED
  • TABLE 233 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 234 NOVARTIS AG: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 235 NOVARTIS AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 236 GILEAD SCIENCES, INC.: COMPANY OVERVIEW
  • TABLE 237 GILEAD SCIENCES, INC.: PRODUCTS OFFERED
  • TABLE 238 GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 239 GILEAD SCIENCES, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 240 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 241 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
  • TABLE 242 SAREPTA THERAPEUTICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 243 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 244 AMGEN, INC.: COMPANY OVERVIEW
  • TABLE 245 AMGEN, INC.: PRODUCTS OFFERED
  • TABLE 246 AMGEN, INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 247 JOHNSON & JOHNSON: COMPANY OVERVIEW
  • TABLE 248 JOHNSON & JOHNSON: PRODUCTS OFFERED
  • TABLE 249 JOHNSON & JOHNSON: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 250 JOHNSON & JOHNSON: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 251 BIOGEN INC.: COMPANY OVERVIEW
  • TABLE 252 BIOGEN INC.: PRODUCTS OFFERED
  • TABLE 253 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 254 BIOGEN INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 255 SMITH+NEPHEW: COMPANY OVERVIEW
  • TABLE 256 SMITH+NEPHEW: PRODUCTS OFFERED
  • TABLE 257 MEDIPOST CO., LTD.: COMPANY OVERVIEW
  • TABLE 258 MEDIPOST: PRODUCTS OFFERED
  • TABLE 259 PRODUCT PIPELINE
  • TABLE 260 MEDIPOST: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 261 MEDIPOST: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 262 JCR PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
  • TABLE 263 JCR PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED
  • TABLE 264 CORESTEM, INC.: COMPANY OVERVIEW
  • TABLE 265 CORESTEM, INC.: PRODUCTS OFFERED
  • TABLE 266 VERICEL CORPORATION: COMPANY OVERVIEW
  • TABLE 267 VERICEL CORPORATION: PRODUCTS OFFERED
  • TABLE 268 VERICEL CORPORATION: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 269 MIMEDX GROUP, INC.: COMPANY OVERVIEW
  • TABLE 270 MIMEDX GROUP, INC.: PRODUCTS OFFERED
  • TABLE 271 MIMEDX GROUP, INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 273 ORGANOGENESIS INC.: COMPANY OVERVIEW
  • TABLE 274 ORGANOGENESIS INC.: PRODUCTS OFFERED
  • TABLE 275 ORGANOGENESIS INC.: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 276 MEDTRONIC: COMPANY OVERVIEW
  • TABLE 277 MEDTRONIC: PRODUCTS OFFERED
  • TABLE 278 MEDTRONIC: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
  • TABLE 279 BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW
  • TABLE 280 BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS OFFERED
  • TABLE 281 BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 282 BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 283 AUTOLUS THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 284 AUTOLUS THERAPEUTICS: PRODUCTS OFFERED
  • TABLE 285 AUTOLUS THERAPEUTICS: PRODUCT APPROVALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 286 AUTOLUS THERAPEUTICS: DEALS, JANUARY 2023-SEPTEMBER 2026
  • TABLE 287 ORTHOCELL LTD.: COMPANY OVERVIEW
  • TABLE 288 MESOBLAST LTD.: COMPANY OVERVIEW
  • TABLE 289 BIORESTORATIVE THERAPIES, INC.: COMPANY OVERVIEW
  • TABLE 290 PLURISTEM THERAPEUTICS INC.: COMPANY OVERVIEW
  • TABLE 291 TEGOSCIENCE: COMPANY OVERVIEW
  • TABLE 292 ANTEROGEN. CO., LTD.: COMPANY OVERVIEW
  • TABLE 293 BLUEBIRD BIO, INC.: COMPANY OVERVIEW
  • TABLE 294 STEMPEUTICS RESEARCH PVT. LTD.: COMPANY OVERVIEW
  • TABLE 295 SIBIONO GENETECH CO. LTD.: COMPANY OVERVIEW
  • TABLE 296 ASPECT BIOSYSTEMS: COMPANY OVERVIEW
  • TABLE 297 ATHERSYS, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 REGENERATIVE MEDICINE MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 REGENERATIVE MEDICINE MARKET: YEARS CONSIDERED
  • FIGURE 3 MARKET SCENARIO
  • FIGURE 4 GLOBAL REGENERATIVE MEDICINE MARKET, 2024-2031
  • FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN REGENERATIVE MEDICINE MARKET, 2023-2026
  • FIGURE 6 DISRUPTIONS INFLUENCING THE GROWTH OF REGENERATIVE MEDICINE MARKET
  • FIGURE 7 HIGH-GROWTH SEGMENTS IN REGENERATIVE MEDICINE MARKET, 2026-2031
  • FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN REGENERATIVE MEDICINE MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
  • FIGURE 9 GROWING ADOPTION OF CELL & GENE THERAPY TO AID GROWTH
  • FIGURE 10 CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN NORTH AMERICA IN 2025
  • FIGURE 11 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 12 CELL THERAPY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 13 REGENERATIVE MEDICINE MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 14 REGENERATIVE MEDICINE MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 15 REGENERATIVE MEDICINE MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 16 REGENERATIVE MEDICINE MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 17 REGENERATIVE MEDICINE MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 18 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
  • FIGURE 19 IMPACT OF AI/GEN AI ON REGENERATIVE MEDICINE MARKET
  • FIGURE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT
  • FIGURE 21 KEY BUYING CRITERIA FOR REGENERATIVE MEDICINE PRODUCTS, BY END USER
  • FIGURE 22 NORTH AMERICA: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 23 ASIA PACIFIC: REGENERATIVE MEDICINE MARKET SNAPSHOT
  • FIGURE 24 REVENUE ANALYSIS OF KEY PLAYERS, 2023-2025 (USD MILLION)
  • FIGURE 25 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2025
  • FIGURE 26 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 27 REGENERATIVE MEDICINE MARKET: COMPANY FOOTPRINT
  • FIGURE 28 REGENERATIVE MEDICINE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 29 EV/EBITDA OF KEY PLAYERS
  • FIGURE 30 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
  • FIGURE 31 REGENERATIVE MEDICINES PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS OF REGENERATIVE MEDICINES INSTRUMENTS
  • FIGURE 32 NOVARTIS AG: COMPANY SNAPSHOT (2025)
  • FIGURE 33 GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 34 SAREPTA THERAPEUTICS: COMPANY SNAPSHOT (2025)
  • FIGURE 35 AMGEN, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 36 JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • FIGURE 37 BIOGEN INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 SMITH+NEPHEW: COMPANY SNAPSHOT (2025)
  • FIGURE 39 MEDIPOST CO., LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 40 JCR PHARMACEUTICALS CO., LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 41 VERICEL CORPORATION: COMPANY SNAPSHOT (2025)
  • FIGURE 42 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 43 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 44 MEDTRONIC: COMPANY SNAPSHOT (2025)
  • FIGURE 45 BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2025)
  • FIGURE 46 AUTOLUS THERAPEUTICS COMPANY: COMPANY SNAPSHOT (2025)
  • FIGURE 47 RESEARCH DESIGN
  • FIGURE 48 BREAKDOWN OF PRIMARIES: REGENERATIVE MEDICINE MARKET
  • FIGURE 49 MARKET SIZE ESTIMATION FOR SUPPLY-SIDE ANALYSIS: REGENERATIVE MEDICINE MARKET, 2025
  • FIGURE 50 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2025
  • FIGURE 51 NOVARTIS AG: REVENUE SHARE ANALYSIS, 2025
  • FIGURE 52 PRODUCT-BASED REVENUE ANALYSIS, 2025
  • FIGURE 53 VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 55 CAGR PROJECTIONS: REGENERATIVE MEDICINE MARKET
  • FIGURE 56 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES IN REGENERATIVE MEDICINE MARKET
  • FIGURE 57 DATA TRIANGULATION METHODOLOGY